Academic Journal
MicroRNA-targeted reprogramming of CD8+ T cells against cancer.
| Title: | MicroRNA-targeted reprogramming of CD8+ T cells against cancer. |
|---|---|
| Authors: | Mao Y; Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.; The First Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Liu Y; The First Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Jing K; The First Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Shao Y; The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Yang K; The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Wu J; The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Zhou X; The Second Clinical Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Wang H; Department of Orthopedics, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China., Fang Z; Department of Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Apr 24; Vol. 17, pp. 1770102. Date of Electronic Publication: 2026 Apr 24 (Print Publication: 2026). |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| MeSH Terms: | MicroRNAs*/genetics , MicroRNAs*/immunology , CD8-Positive T-Lymphocytes*/immunology , CD8-Positive T-Lymphocytes*/metabolism , Neoplasms*/immunology , Neoplasms*/genetics , Neoplasms*/therapy , Cellular Reprogramming*/genetics , Cellular Reprogramming*/immunology, Tumor Microenvironment/immunology ; Tumor Microenvironment/genetics ; Humans ; Animals ; Exosomes ; Gene Expression Regulation, Neoplastic ; Metabolic Reprogramming |
| Abstract: | This scoping review highlights the critical role of microRNAs (miRNAs) in mediating the bidirectional crosstalk between CD8+ T cells and tumor cells within the immunosuppressive tumor microenvironment (TME). Specific miRNAs (e.g., miR-155, miR-340-5p) orchestrate CD8+ T cell function by fine-tuning immune checkpoints (PD-1/PD-L1), metabolic reprogramming, and epigenetic states. Conversely, CD8+ T cells influence tumor behavior via exosomal miRNA transfer (e.g., miR-765). Our analysis reveals both pan-cancer mechanisms, such as PD-1/PD-L1 regulation, and tissue-specific miRNA functions (e.g., miR-143 in melanoma). To overcome translational challenges like off-target effects, innovative delivery strategies using lipid nanoparticles and engineered exosomes are being developed. This review provides a mechanistic framework for miRNA-mediated interactions, offers clinical insights for novel combination therapies, and assesses future directions, thereby advancing the development of precision immunotherapies. (Copyright © 2026 Mao, Liu, Jing, Shao, Yang, Wu, Zhou, Wang and Fang.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| Contributed Indexing: | Keywords: CD8+T cell; cancer; cellular pathway; immunology; microRNA |
| Substance Nomenclature: | 0 (MicroRNAs) |
| Entry Date(s): | Date Created: 20260511 Date Completed: 20260716 Latest Revision: 20260716 |
| Update Code: | 20260717 |
| PubMed Central ID: | PMC13152852 |
| DOI: | 10.3389/fimmu.2026.1770102 |
| PMID: | 42112385 |
| Database: | MEDLINE |
Be the first to leave a comment!